Bone lesions on baseline staging rectal MRI: prevalence and significance in patients with rectal adenocarcinoma

Abdom Radiol (NY). 2021 Jun;46(6):2423-2431. doi: 10.1007/s00261-020-02923-7. Epub 2021 Feb 4.

Abstract

A T1 sequence on routine baseline staging rectal magnetic resonance imaging (MRI) is thought to help detect bone lesions. Our primary aim was to evaluate the incidence of bone lesions encountered on baseline staging rectal MRI, particularly the prevalence of bone metastases. This retrospective study included patients with rectal adenocarcinoma who underwent baseline rectal MRI at our institution between January 2010 and December 2017. The MRI report was reviewed for presence of bone lesions. When found, lesion type, presence of axial T1 non-fat-suppressed sequence, primary tumor T-stage, and presence of other organ metastases were recorded. In the absence of bone biopsy, the reference standard was follow-up imaging via computed tomography (CT), MRI, and/or positron emission tomography/CT (PET/CT) ≥ 1 year after the baseline MRI. The Wilcoxon rank-sum test and Fisher's exact test were used to compare clinicopathologic data of patients with malignant or benign bone lesions. A total of 1197 patients were included. 62/1197 patients (mean age 56.8 years (SD: 13.8), with 39 men) had bone lesions on baseline imaging, with 6 being bone metastases (0.5%, 95% CI 0.2%-1.1%). Of the 6 patients with bone metastases, 5/6 had other metastases (i.e., liver, lung) at baseline. Bone metastases on baseline rectal MRI performed for rectal adenocarcinoma are extremely rare. Furthermore, bone metastases without other organ (i.e., liver, lung) involvement is extremely rare.

Keywords: Bone neoplasm; Magnetic resonance imaging; Rectal neoplasm.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenocarcinoma* / diagnostic imaging
  • Adenocarcinoma* / epidemiology
  • Adenocarcinoma* / pathology
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Positron Emission Tomography Computed Tomography*
  • Positron-Emission Tomography
  • Prevalence
  • Radiopharmaceuticals
  • Retrospective Studies

Substances

  • Radiopharmaceuticals